Search alternatives:
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
_ patient » _ patients (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
_ patient » _ patients (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
-
1
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
2
-
3
-
4
-
5
-
6
-
7
Baseline patient characteristics.
Published 2025“…This study was conducted as part of a randomized controlled trial originally designed to assess the effects of s-ketamine conditioning on pain sensitivity in patients with fibromyalgia syndrome. Participants were randomly assigned to receive an infusion of either s-ketamine (0.3 mg kg<sup>-1</sup> h<sup>-1</sup>), midazolam (0.05 mg kg<sup>-1</sup> h<sup>-1</sup>), or saline in a blinded fashion. …”
-
8
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
9
-
10
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
11
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
12
-
13
-
14
-
15
-
16
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
17
-
18
-
19
-
20